- Author:
Song JIN
1
Author Information
- Publication Type:Journal Article
- Keywords: Homozygous familial hypercholesterolemia; Lipid drug; Lomitapide; Microsomal triglyceride transfer protein
- From: Chinese Pharmaceutical Journal 2013;48(22):1972-1974
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To review the pharmacological actions and related clinical research about the efficacy and safety of lomitapide, which is a new kind of medication for cholesterol disorder-microsomal triglyceride transfer protein inhibitor. METHODS: The domestic and oversea pertinent literatures since 2007 were searched. RESULTS: Lomitapide can performe well in clinic effects and tolerance for homozygous familial hypercholesterolemia. CONCLUSION: Lomitapide can be an effective adjuvant for patients with homozygous familial hypercholesterolemia.